https://ir.skyebioscience.com/news-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_e076ea37d6bf897725c32eff044cb88a/skyebioscience/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.skyebioscience.com/news-releases/detail/260/skye-announces-cohort-review-committee-approved-opening-of-cohort-2-based-on-favorable-safety-data-from-first-four-participants-treated-in-cohort-1 Wed, 20 May 26 07:00:00 -0400 https://ir.skyebioscience.com/news-releases/detail/260/skye-announces-cohort-review-committee-approved-opening-of-cohort-2-based-on-favorable-safety-data-from-first-four-participants-treated-in-cohort-1 https://ir.skyebioscience.com/news-releases/detail/259/update-skye-bioscience-reports-first-quarter-2026-financial-results-and-business-update Tue, 12 May 26 13:33:00 -0400 https://ir.skyebioscience.com/news-releases/detail/259/update-skye-bioscience-reports-first-quarter-2026-financial-results-and-business-update https://ir.skyebioscience.com/news-releases/detail/258/skye-bioscience-reports-first-quarter-2026-financial-results-and-business-update Mon, 11 May 26 16:01:00 -0400 https://ir.skyebioscience.com/news-releases/detail/258/skye-bioscience-reports-first-quarter-2026-financial-results-and-business-update https://ir.skyebioscience.com/news-releases/detail/257/skye-bioscience-presenting-at-glp-1-based-therapeutics-summit Tue, 07 Apr 26 07:00:00 -0400 https://ir.skyebioscience.com/news-releases/detail/257/skye-bioscience-presenting-at-glp-1-based-therapeutics-summit https://ir.skyebioscience.com/news-releases/detail/256/skye-bioscience-treats-first-patient-in-nimacimab-higher-dose-expansion-study-evaluating-exposure-response-to-inform-phase-2b-dose-selection-for-glp-1-combination-development Thu, 02 Apr 26 07:00:00 -0400 https://ir.skyebioscience.com/news-releases/detail/256/skye-bioscience-treats-first-patient-in-nimacimab-higher-dose-expansion-study-evaluating-exposure-response-to-inform-phase-2b-dose-selection-for-glp-1-combination-development https://ir.skyebioscience.com/news-releases/detail/255/skye-bioscience-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update Tue, 10 Mar 26 16:01:00 -0400 https://ir.skyebioscience.com/news-releases/detail/255/skye-bioscience-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update https://ir.skyebioscience.com/news-releases/detail/254/skye-bioscience-to-announce-2025-financial-results-and-business-update-on-march-10-2026 Thu, 05 Mar 26 07:00:00 -0500 https://ir.skyebioscience.com/news-releases/detail/254/skye-bioscience-to-announce-2025-financial-results-and-business-update-on-march-10-2026 https://ir.skyebioscience.com/news-releases/detail/253/skye-reports-positive-cbeyond-phase-2a-extension-interim-study-results-for-nimacimab-in-combination-with-semaglutide Mon, 02 Feb 26 07:00:00 -0500 https://ir.skyebioscience.com/news-releases/detail/253/skye-reports-positive-cbeyond-phase-2a-extension-interim-study-results-for-nimacimab-in-combination-with-semaglutide https://ir.skyebioscience.com/news-releases/detail/252/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference Thu, 29 Jan 26 07:00:00 -0500 https://ir.skyebioscience.com/news-releases/detail/252/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference https://ir.skyebioscience.com/news-releases/detail/251/skye-bioscience-to-present-poster-at-keystone-obesity-conference Wed, 21 Jan 26 07:00:00 -0500 https://ir.skyebioscience.com/news-releases/detail/251/skye-bioscience-to-present-poster-at-keystone-obesity-conference